**Wanbury Limited**
**Regd. Office**: BSEL Tech Park,
B-Wing, 10th Floor, Sector-30A,
Opp. Vashi Railway Station,
Vashi, Navi Mumbai 400703
Maharashtra, INDIA
Tel: +91-22-6794 2222
+91-22-7196 3222
CIN: L51900MH1988PLC048455
Email: info@wanbury.com
Website: www.wanbury.com

November 12, 2026

| | |
|---|---|
| To<br>BSE Limited<br>PJ. Towers,<br>Dalal Street<br>Mumbai-400 001.<br>**Script Code:** 524212 | To<br>National Stock Exchange of India Ltd,<br>Exchange Plaza, Bandra Kurla Complex,<br>Bandra (East),<br>Mumbai - 400 051.<br>**Script Code:** WANBURY |

**Dear Sir/Madam**

**Sub.: Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HCl EP grade.**

Pursuant to Regulation 30 of SEBI LODR, we wish to inform you as under:

Please find herewith the press release highlighting that Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HCl EP grade. This is the third consecutive approval from ANVISA to Wanbury's APIs enabling customer to use its APIs for formulations. The Company is committed to meet customer demands & strive for quality excellence.

The Company has initiated talks with various customers to increase the volume of business from its customers.

This is for your information and records.

**Thanking you.**

**Yours faithfully,**
**For Wanbury Limited**

JITENDRA JAYANTILAL GANDHI
Digitally signed by JITENDRA JAYANTILAL GANDHI
Date: 2026.11.12 11:09:51 +05'30'

**Jitendra J. Gandhi**
**Company Secretary**